HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
YM 9429
a potent and specific teratogen; induces cleft palate in CD rats; inhibits dehydrocholesterol reductase
Also Known As:
YM-9429; YM9429; cis-1-(4-(p-monthane-8-yloxy)phenyl)piperidine
Networked:
5
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Piperidines: 17
YM 9429: 5
Experts
1.
Funae, Y
: 1 article (02/2000)
2.
Imaoka, S
: 1 article (02/2000)
3.
Numazawa, S
: 1 article (02/2000)
4.
Shibata, M
: 1 article (02/2000)
5.
Yoshida, T
: 1 article (02/2000)
Related Diseases
1.
Cleft Palate (Palate, Cleft)
02/01/2000 - "
A teratogenic compound cis-1-[-4-(p-menthane-8-yloxy)phenyl]piperadine (YM9429) selectively induces skeletal malformations characterized by cleft palate in rat fetuses.
"
02/01/1995 - "
YM9429 induced fetal cleft palate in vivo in CD rats when dams were orally treated during days 11-14 of pregnancy at dose of 500 mg/kg/day, but no abnormalities were detected when treated on days 15-16 (Shibata, 1993).
"
08/01/1993 - "
YM9429 induced cleft palate and specific skeletal variations including accessory cervical and lumbar ribs or excessive formation of the 7th lumbar vertebra by oral treatment during the organogenetic periods.
"
08/14/1996 - "
A teratogenic compound cis-1-[4-(p-menthane 8-yloxy)phenyl]piperidine (YM9429) induces cleft palate selectively in rat fetuses.
"
09/01/1996 - "
YM 9429 (cis-1-[4-(p-menthan-8-yloxy)phenyl]piperidine) is a hypolipidemic agent with a potent and specific teratogenicity, inducing cleft palate and skeletal variations in rats.
"
2.
Smith-Lemli-Opitz Syndrome
09/01/1996 - "
These results suggest that YM 9429 induced developmental abnormalities in rats by the same mechanism as the Smith-Lemli-Opitz syndrome.
"
09/01/1996 - "
Since cleft palate is generally observed in the Smith-Lemli-Opitz syndrome, a common syndrome of multiple congenital anomalies caused by reduced activity of 7-dehydrocholesterol delta 7-reductase (3 beta-hydroxysteroid delta 7-reductase), the final enzyme in the cholesterol biosynthetic pathway, YM 9429 was suspected of being an inhibitor of this enzyme.
"
3.
Experimental Liver Neoplasms
09/01/1996 - "
To prove this hypothesis, YM 9429 was added to cultured human skin fibroblasts and to cultured Morris hepatoma cells and incubated with [5-3H]mevalonolactone.
"
4.
Carcinoma (Carcinomatosis)
08/14/1996 - "
The effect of YM9429 on chondrogenic differentiation was investigated using mouse embryonic carcinoma ATDC5 cells that produce chondrocyte specific extracellular matrix upon insulin stimulation.
"
08/14/1996 - "
Inhibition of insulin-induced chondrogenic differentiation of embryonic carcinoma cells by a teratogenic compound YM9429.
"
Related Drugs and Biologics
1.
Cholesterol
2.
piperidine
3.
Teratogens
4.
Phospholipids (Phosphatides)
5.
Oxidoreductases (Dehydrogenase)
6.
Insulin (Novolin)
7.
Enzymes
8.
Hypolipidemic Agents (Antihyperlipidemics)
9.
7-dehydrocholesterol
10.
mevalonolactone